The Boston biotech Karuna Therapeutics, which is seeking approval of a novel drug for schizophrenia, is already talking about more than doubling its workforce next year if the Food and Drug ...

Karuna Therapeutics KRTX announced the submission of a new drug application (“NDA”) with the FDA seeking approval for its lead candidate KarXT, as a potential treatment of schizophrenia. If approved, ...

AbbVie and Bristol Myers Squibb each capped last year with multibillion-dollar acquisitions of companies developing new drugs for psychiatric conditions. But they weren’t the only interested buyers, ...

Karuna's stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers' drug pipeline after competition ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (“Karuna,” formerly Karuna Pharmaceuticals), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders ...

Karuna Therapeutics’ multi-year mission to resurrect an old Eli Lilly drug has ended in clinical success. The biotech has emerged from the phase 3 Emergent-2 trial with evidence showing its therapy ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric ...

Shares of Karuna Therapeutics (NASDAQ:KRTX) had skyrocketed 233.1% higher as of 11:03 a.m. EST on Monday. The biopharmaceutical company announced positive results earlier in the morning from a phase 2 ...